Clearpoint Ventures in Melbourne, Victoria, Australia | Business service

Clearpoint Ventures

Locality: Melbourne, Victoria, Australia

Phone: +61 1300 736 273

Address: Lvl 18, 1 Nicholson Street 3002 Melbourne, VIC, Australia

Website: http://clearpoint.ventures/

Likes: 139

Add/Update information

Reviews

Tags

• Business service
• Business consultant

23.01.2022 Choose Aussie Clearpoint Ventures and Brandwood CKC explain why US companies should do their R&D in Australia Clearpoint Ventures is pleased to be associated with SBDC and Brandwood CKC in hosting a webinar on the opportunities available to US-based Life Science companies that wish to undertake (some or all) of their R&D in Australia.... With a world-class research network, globally recognised clinical trial infrastructure, regulatory expertise, and generous R&D Tax benefits, Australia offers a number of attractive opportunities. The webinar will demonstrate the relative ease of: 1. Setting up and running an entity in Australia. 2. Collaborating with local Universities and Research Centres to undertake research on your behalf. 3. Arranging a CRO to undertake Clinical Trials on your behalf. 4. Achieving Regulatory compliance with Australia’s version of the FDA (Therapeutic Goods Administration). Topics to be covered: - Benefits of the R&D Tax Incentive Program - Leveraging Australian Clinical Trials globally - Australia's regulatory framework for MedTechs - Steps to achieve expedited Clinical Trial set-up process in Australia If you have any questions about the topic, please feel free to reach out to: [email protected]

22.01.2022 2020 EUREKA International Innovation & Entrepreneurship Competition Participants will have opportunity to win up to $20,000 cash prize. All projects will be focused on 4 industry sectors:... 1. Healthcare and Biotechnology 2. Advanced Manufacturing 3. IT & Digital Tech 4. Food & Agriculture This year, Eureka Technology running the competition online. Shortlisted teams will also have opportunity to enter the international competition ( online) with teams from USA, Europe and Asia to compete for additional prizes (up to $10,000) and gain access to business networks, partnerships and funding support. The winner of the competition will be able to access designated government funds (up to $1 million, conditions apply) and business facilitation services. Application is open now and it will be closed on 8th of June. The competition final will be held at the end of July (exact date TBC).

21.01.2022 Pavel Reddy and Joel Cranshaw from Clearpoint Ventures received a warm acknowledgement from Rita Sellars for our work to assist the The Startup Collective and for our R&D Tax work for pH Factor. Rita and her team are awesome to work with, and we look forward to a long and productive collaboration.

20.01.2022 Australian applicants flock to COVID-19 clinical trials

20.01.2022 JobKeeper Payments: Eligible R&D Tax Expenditure Or Not? The ATO has recently issued a draft tax determination (TD 2020/D1) that proposes the treatment of how notional deductions and the ‘expenditure not at risk’ provisions in section 355-405 of ITAA97 applies specifically to JobKeeper payments that are received by an entity undertaking eligible R&D.... In essence, the ‘expenditure not at risk’ provisions disallows any expenditure that an R&D entity (or an associate) could reasonably be expected to receive in ‘consideration’. There is currently some dispute regarding the ordinary meaning of the word consideration. For more details on this, refer to this article: https://taxandsupernewsroom.com.au/the-rd-offset-at-risk-/ However, what is crucial here for R&D entities, is that this proposed tax determination adds another layer of complexity to an already battered R&D Tax Incentive program. Companies are rightfully frustrated at the possibility of amendments to F20 R&D Tax claims, uncertainty of how to manage the transition into FY21 as this is ultimately resolved. There are a few points to consider: 1. Are amounts from current government support mechanisms excluded from being claimed as eligible R&D expenditure? Federal and State grants are currently subject to a clawback mechanism. This could be somewhat easier (& beneficial to R&D entities) to manage. 2. Where a R&D entity is able to access tax offsets (in general), those amounts are not excluded when the entity re-invests those amounts back into R&D activities? Why should JobKeeper be any different? Our advice for R&D entities is to TRACK employee (or associate) R&D time. Entities claiming the R&D Tax Incentive ought to be doing this on a contemporaneous basis anyway. When a final determination is made, and if the JobKeeper payments are deemed ‘expenditure not at risk’ (i.e., ineligible), R&D entities will be able to fairly easily identify the JobKeeper amounts as those have been tracked against R&D hours and apply the necessary adjustments. The adjustments may be effected either through the clawback mechanism, or by withdrawing those amounts, via an amended tax return. We hope that sense prevails, as SMEs especially, need support and strong guidance through these challenging times. Should you require additional guidance on this issue, or wish to discuss how this determination could affect your R&D Tax claim, please reach out to us.

18.01.2022 Australia's Biomedical Translational Bridge (BTB) Program: $1M in matching funding for COCID-19 research

16.01.2022 Our dear friend, Victoria Wells, co-founder at 3DEME:

14.01.2022 Smart Cities tech start-up competition

11.01.2022 Clearpoint Ventures is excited to be a part of CUB Club of United Business. We're keen to share our expertise with that business community, and, in turn, to learn from the other members.

08.01.2022 Switch It On Information Seminar

08.01.2022 From gins to non-alcoholic Sapiir spirits and hand sanitisers: The Agility of Brunswick Aces.

07.01.2022 R&D Made Simple

07.01.2022 Planning for Financial Year End R&D Tax Incentive Claims As we approach the end of the 2019-20 financial year (FY20), you’re hopefully familiar with my regular ‘touch point’ process. This involves checking in with you to ensure that there is ongoing compliance with the R&D Tax Incentive program.... A few of the more important issues that I like to cover off on are: 1. Are you tracking all the developments or activities that are being undertaken in FY20? This is to ensure that all material developments (significant labour costs and/or material costs) are tracked as they are being undertaken. 2. Are you maintaining adequate contemporaneous documentation of all the work described in 1. above (including non-R&D activities)? Maintaining tangible evidence of the R&D entity’s activities is important as it allows us to clearly differentiate between the eligible R&D activities that we’re claiming and the ineligible activities. 3. Are you ensuring that you and your staff are reliably tracking time spent on the eligible R&D activities on a contemporaneous basis? Often, software tracking systems do not (or are not able to) accurately capture the eligible supporting activities. These are typically tasks undertaken that directly support the experimental activities at the time that the latter are being undertaken. 4. Are you also ensuring that any 3rd party Contractors providing work/services relating to the eligible R&D activities are covered by a comprehensive Contract? That Contract should also be unequivocally clear about the ownership of the IP resulting from the R&D activities vesting with the R&D entity. Are you also sure that all Contract work is being undertaken in Australia? If not, these activities and costs are not eligible. 5. If there are to be any unpaid payments to Associates (including Founders and Directors), these should be addressed well before 30 June 2020. If you’re in any doubt about this particular tax provision, and how it might apply to you, please contact us.

07.01.2022 Eleni Nott and Pavel Reddy were part of a group of enthusiastic mentors guiding the Casey startup community at their inaugural INNovation Crowd Bootcamp in June 2019. Eleni Nott is herself an entrepreneur and founder, and still collaborates with Clearpoint Ventures.

06.01.2022 After the 1st USA-UK-EU #CoffeeBuddies event that had a 3am start for me (yes - 03:00 !), I look forward to a 'normal' time for the 2nd Aus-UK event on 11 November hosted by #CoffeeBuddies and supported by Clearpoint Ventures. The inimitable team of duo Tony Sedgwick and Graham Combe have managed to pull together another stellar line-up of Life Science execs and funders in a relaxed, "camera-on" Zoom format that encourages interaction and Q&As by attendees in each of the shor...t presentation and pitch sessions. The small-group virtual networking (~ speed business dating) is genuinely friendly, and a great opportunity to meet and connect with our northern mates. For more details, please click on the Eventbrite link in the article below, or reach out directly to myself, Dr. Pavel Reddy or Joel Cranshaw. We look forward to seeing you on the night!

06.01.2022 Thank you Craig Newton for the kind recommendation.

06.01.2022 Imagion Biosystems posts about an exciting new application of its proprietary nanoparticle technology.

05.01.2022 Australia beyond COVID-19: Push to develop and enhance local expertise and capabilities.

05.01.2022 We've been very fortunate to contribute to this Brandwood CKC post, with Pavel Reddy being interviewed by Luis Jimenez.

03.01.2022 Some insightful information on the spread of coronaviruses: "Successful Infection = Exposure to Virus x Time"